UCB:EBR
UCB SA
204,60 €
arrow_downward
−0,68%(−1,40) 1 D
16. okt., 17:37:21 GMT+2 · EUR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for UCB …
Åpne
204,50 €
Høy
205,10 €
Lav
201,30 €
Markedsverdi
39,39 mrd.
Snittvolum
248,57k
Volum
324,45k
Utbytte
0,50 %
Kvartalsvis utbytte
0,25 €
Første dato etter utbytte
4. mai 2026
P/E-forhold
18,09
52 u høy
289,50 €
52 u lav
197,45 €
EPS
11,31 €
Utestående aksjer
194,51 mill.
Antall ansatte
9k
Åpne
204,50 €
Høy
205,10 €
Lav
201,30 €
Markedsverdi
39,39 mrd.
Snittvolum
248,57k
Volum
324,45k
Utbytte
0,50 %
Kvartalsvis utbytte
0,25 €
Første dato etter utbytte
4. mai 2026
P/E-forhold
18,09
52 u høy
289,50 €
52 u lav
197,45 €
EPS
11,31 €
Utestående aksjer
194,51 mill.
Antall ansatte
9k
Nyhetssaker
Fra nettkilder og nyhetspartnere
ad-hoc-news.de
·
for 16 timer siden
UCB launches Wear It Out: what it means for UCB stock
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Om UCB SA
Administrerende direktørJean-Christophe Tellier
Ansatte9k
Grunnlagt18. jan. 1928
Hovedkontor-
Sektor-
Nettsteducb.com